IL-6 blockade in chronic inflammatory diseases.

Item

http://www.wikidata.org/entity/Q38261783

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh

2014年學術文章

@zh-hant

name

IL-6 blockade in chronic inflammatory diseases.

@en

type

Item

label

IL-6 blockade in chronic inflammatory diseases.

@en

prefLabel

IL-6 blockade in chronic inflammatory diseases.

@en

P1476

IL-6 blockade in chronic inflammatory diseases.

@en

P2093

Antonia Puchner

http://www.w3.org/2001/XMLSchema#string

P2860

Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study

Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)

Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic dr

A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease.

Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study.

Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials.

Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial.

Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study.

Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy.

Interleukin 6 promotes murine lupus in NZB/NZW F1 mice.

P2888

s10354-014-0321-x

P304

14-22

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10354-014-0321-X

http://www.w3.org/2001/XMLSchema#string

P433

1-2

http://www.w3.org/2001/XMLSchema#string

P478

165

http://www.w3.org/2001/XMLSchema#string

P50

S Blüml

P577

2014-10-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1033614443

http://www.w3.org/2001/XMLSchema#string

P698

25335457

http://www.w3.org/2001/XMLSchema#string

IL-6 blockade in chronic inflammatory diseases.

about

P2860

P2860

IL-6 blockade in chronic inflammatory diseases.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698